Oncology Institute (TOI) Expected to Announce Earnings on Wednesday

Key Points

• Oncology Institute is set to announce its Q2 2025 earnings on August 13th, with analysts predicting earnings of ($0.13) per share and revenue of $112.56 million.
• Insider selling has been notable, with Director Brad Hively selling nearly 2 million shares, representing a 76.61% decrease in his ownership.
• Goldman Sachs recently acquired a new stake in Oncology Institute, purchasing 115,140 shares, which reflects increasing institutional interest in the stock.

Oncology Institute (NASDAQ:TOI - Get Free Report) is anticipated to release its Q2 2025 earnings data after the market closes on Wednesday, August 13th. Analysts expect Oncology Institute to post earnings of ($0.13) per share and revenue of $112.56 million for the quarter. Oncology Institute has set its FY 2025 guidance at EPS.

Oncology Institute (NASDAQ:TOI - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter. The company had revenue of $104.41 million for the quarter. Oncology Institute had a negative net margin of 15.38% and a negative return on equity of 445.02%.

Oncology Institute Stock Performance

Oncology Institute stock traded up $0.12 during midday trading on Friday, reaching $4.28. 1,769,661 shares of the company traded hands, compared to its average volume of 2,216,191. Oncology Institute has a 12 month low of $0.13 and a 12 month high of $4.50. The company has a debt-to-equity ratio of 14.58, a current ratio of 1.79 and a quick ratio of 1.59. The business has a 50 day moving average of $3.00 and a two-hundred day moving average of $2.11. The firm has a market capitalization of $381.90 million, a price-to-earnings ratio of -6.11 and a beta of 0.08.

Analyst Upgrades and Downgrades

TOI has been the topic of a number of recent research reports. Noble Financial initiated coverage on Oncology Institute in a report on Wednesday, July 23rd. They issued an "outperform" rating and a $8.00 target price on the stock. B. Riley began coverage on shares of Oncology Institute in a research note on Wednesday, July 16th. They issued a "buy" rating and a $6.00 price objective on the stock. Finally, BTIG Research began coverage on shares of Oncology Institute in a research report on Thursday, May 15th. They set a "buy" rating and a $7.00 target price for the company.

Insider Activity

In related news, Director Brad Hively sold 1,976,137 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $2.87, for a total value of $5,671,513.19. Following the completion of the sale, the director directly owned 603,501 shares of the company's stock, valued at approximately $1,732,047.87. This represents a 76.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Growth I. L.P. M33 sold 76,324 shares of Oncology Institute stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $3.05, for a total transaction of $232,788.20. Following the transaction, the director directly owned 1,272,724 shares in the company, valued at $3,881,808.20. This represents a 5.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 4,726,137 shares of company stock valued at $13,379,013 in the last three months. 8.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Oncology Institute

Institutional investors and hedge funds have recently modified their holdings of the company. Cetera Investment Advisers grew its holdings in Oncology Institute by 35.0% during the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company's stock valued at $36,000 after buying an additional 4,545 shares in the last quarter. Goldman Sachs Group Inc. bought a new position in shares of Oncology Institute during the first quarter worth $131,000. Finally, Geode Capital Management LLC boosted its position in shares of Oncology Institute by 231.7% during the second quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company's stock worth $2,623,000 after acquiring an additional 893,696 shares during the last quarter. 36.86% of the stock is currently owned by institutional investors.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.